Management

Each member of the team at Genesys Capital brings significant knowledge and expertise in the high technology and biotechnology sectors.

Kent Plumley | Co-Founder and Partner

Mr. Plumley is Co-Founder and Partner of Genesys Capital. Until his recent retirement as a partner from Osler, Hoskin & Harcourt LLP he was a member of the Business Law, Intellectual Property and Technology Law departments of that firm. During his legal and business career Mr. Plumley spent more than 35 years advising and raising venture and equity capital through private and public financing for many of Canada's successful high technology companies. These include Mitel Corporation, Newbridge Networks Corporation and several Newridge affiliate companies: Cambrian Systems Corporation, TimeStep Corporation, Vienna Systems, CrossKeys Systems Corporation and Bridgewater Systems. Mr. Plumley was also a founding investor and director of several of these companies. His high technology affiliations include Zarlink Corporation, and In-Touch Systems among others.

Mr. Plumley has been an active participant in business and community affairs throughout his career. He is a past member and ongoing supporter of the Board of Trustees and Finance and Audit Committee of The University of Ottawa Heart Institute Foundation. He is also a supporter of the newly opened Sprott Centre for Stem Cell Research, a part of the Ottawa Health Research Institute (OHRI). Other involvements include past directorships of the Stem Cell Network, Ottawa Life Sciences Council and Photonics Research Ontario (PRO). For many years he was a member of the Ottawa Centre for Research and Innovation (OCRI), Ottawa's lead economic development corporation.

In 2008 Mr. Plumley completed the maximum term of 12 years as a member of the Board of Trustees for Queen's University but remains a member of the Board's Advancement Committee and a Director of PARTEQ, the Queen's University licensing and technology transfer agency. He is a former member of the Queen's School of Business Advisory Council. He also served as a representative of Osler, Hoskin & Harcourt to the Advisory Board for the Centre for Innovation Law & Policy at the University of Toronto Law School.

Mr. Plumley earned a Bachelor of Science in Chemical Engineering from Queen's University in 1960 and an LLB in 1963, also from Queen's. He was called to the Bar of Ontario in 1965 and is a registered Patent and Trade Mark agent.

Kelly Holman | Co-Founder and Managing Director

Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $100 million across 20 investments. He currently serves on the Board of Directors of Epocal Inc., and is a past director of Affinium Pharmaceuticals, Insception Biosciences, Interface Biologics and Zelos Therapeutics. Mr. Holman is active in deal origination and company creation and has advised Canada's National Biotechnology Advisory Committee on strategies for financing start-up and early-stage biotechnology companies.

Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corp. During his tenure at MDS, he was involved in all stages of investment from start-up and early-stage to mezzanine stage and public company investing.

Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer's disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

Damian Lamb | Co-Founder and Managing Director

Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $225 million in venture capital funds, and has been involved in deploying over $100 million in 20 investments. He currently serves on the Boards of Affinium Pharmaceuticals Inc., Profound Medical Inc. and the Centre for Probe Development and Commercialization at McMaster University. He has served on the Board of Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences and was a judge for the BioNorth Top 10 Canadian Life Sciences Companies contest from 2000 - 2008.

Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with an M.S. in Molecular Neurobiology and also holds an MBA from Queen's University.

Jamie Stiff | Partner

Mr. Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007. He brings to Genesys a unique combination of scientific understanding and business acumen and has demonstrated an innate affinity for the business of venture capital. Since joining the firm, Mr. Stiff has gained significant deal experience across a number of transactions.

Mr. Stiff currently serves on the board of Allostera Pharma and sits as an observer on the board of NeurAxon Inc. Past board roles include directorships at Matregen Corp. and Stempath Inc. and board observer at Zelos Therapeutics and Interface Biologics.

Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience combined with an academic background in Biology has provided significant technical knowledge of many areas of life sciences and provides for a keen eye for sourcing promising early stage deal flow through the company's proprietary Technology Access Partnerships.

Mr. Stiff holds a Bachelor of Science (Honours) in Biology from Queen's University and an MBA from the Rotman School of Management at the University of Toronto.

Jennifer Williams | Director of Finance and Operations

Ms. Williams is Director of Finance and Operations at Genesys Capital. Ms. Williams joined Genesys Capital in 2003. During her career with Genesys she has worked closely with the team to develop the operations and is responsible for finance, human resources and administration.

Ms. Williams graduated from the University of Guelph with an Honours Bachelor of Commerce and holds an MBA from Queen's University.

Jack Cashman | Venture Partner

In 2006, Mr. Cashman joined Genesys as a venture partner to provide strategic and operational support for companies within the Genesys portfolio and help to identify new investment opportunities.

Mr. Cashman has over 35 years operating experience in the life sciences industry at the highest corporate levels, spanning a spectrum of roles from corporate strategy development to operational management, business development and marketing. From 1989 to 1996 he served as Chairman and co-CEO of R.P. Scherer [now part of Cardinal Health Inc. (NYSE:CAH)], an international developer and manufacturer of drug delivery systems, operating a global network of 20 facilities in 12 countries. During Mr. Cashman's tenure revenues and profits more than doubled, rising to over half a billion dollars and more than 100 million dollars respectively.

Mr. Cashman is currently the Non-Executive Chairman of Vectura Group Plc. (LSE:VEC), a Director of Transat AT Inc. (TSX: TRZ-B, TRZ-A) and a Director of Telesat Inc. (Canada). From 2002 - 2005 he was the Non-Executive Chairman of Advanced Surgical Concepts of Ireland.

Frédéric Porte | Venture Partner

In 2008, Mr. Porte joined Genesys as a venture partner to provide strategic and operational support for companies within the Genesys portfolio and help to identify new investment opportunities.

Mr. Frédéric Porte is a seasoned entrepreneur and businessman with more than 25 years of experience in the life sciences industry. During his career, Mr. Porte has founded three successful companies. He is currently the President and Founder of Medipress Management Inc., a firm offering financial and strategic services to healthcare and venture capital organizations for the evaluation of M&A and strategic alliances.

Prior to that, he founded in 1987 Clinidata, a software and communication company developed in association with Royal Bank Capital Corporation, which specialized in healthcare applications. Clinidata developed effective and sophisticated technologies supported by multinational corporations such as Merck, Pfizer, J&J, Schering Plough and Smith Kline Beecham, combined with strategic alliances with managed care organizations and professional associations. Clinidata was acquired in 1994 by the pharmaceutical company Hoechst Marion Roussel. In 1980, he created and managed L'Actualité Médicale, a leading Canadian medical publishing company which was later acquired by MacLean Hunter.

Mr. Porte has a degree in Business Administration and Finance from l'École Supérieure de Commerce de Lyon (France) and a D.E.A. in Information Sciences from the University of Sorbonne (France). Mr. Porte is a member of the Board of Directors of Labopharm Inc. He is also the Chairman of the board of Ambrilia Biopharma and of i3 vision.

Advisory Board

The Genesys Advisory Board consists of experienced senior executives from the biotechnology, pharmaceutical, high technology, financial and scientific communities.

The Genesys Advisory Board includes:
John D. Mendlein, PhD, Executive Chairman, Fate Therapeutics

Dr. John Mendlein is Executive Chairman of four privately held biotech companies in San Diego: Fate Therapeutics (drugs for stem cells), aTyr Pharm (novel protein therapeutics), Chimeros (novel polynucleotide therapeutics) and Alevium (novel drugs for GI discomfort). Prior to his involvement in these enterprises, he served as CEO of Adnexus Therapeutics (a pioneer of a new class of protein therapeutics) from June 2005 until October 2007, at which time the privately-held, Boston based biotechnology company was purchased by Bristol-Myers Squibb Company (BMY) in a transaction valued at more than $505 million.

Previously, Dr. Mendlein served as Chairman and CEO at Affinium Pharmaceuticals, Inc. and served in a variety of roles, including board member, general counsel and chief knowledge officer at Aurora Biosciences (acquired by Vertex Pharmaceuticals, VRTX), a biotechnology company focused on discovering drugs for kinases, g-protein coupled receptors and ion channels. He has worked as an attorney at Cooley LLP, a law firm, in its life sciences and technology litigation practice groups, at Smith Kline & French, [now GlaxoSmithKline (GSK)], as a scientist in the Department of Molecular Biology and Protein Expression, and served as a board member of Monogram Biosciences (MGRM, acquired by Lab Corp, LH).

Dr. Mendlein is currently an advisory board member of Genesys Capital, a founder and board member of Homes for Sudan, a not for profit in Boston, and a scientific advisory board member for Ocean Discovery Institute, a not for profit in San Diego.

Dr. Mendlein is the author or inventor of over 40 publications and patents. He has won various awards for his work in biotechnology and science, as well as write-ups of various business endeavors in the Wall Street Journal, Financial Times and Newsweek. Dr. Mendlein earned his PhD in Physiology and Biophysics from the University of California, Los Angeles, a J.D. from the University of California Hastings School of Law and a B.S. in Biology from the University of Miami.

Peter H. St George-Hyslop, MD, F.R.C.P. (C), F.R.S., Professor, University of Toronto
Professor of Experimental Neuroscience, University of Cambridge

Dr. St George-Hyslop is a leading neurologist and molecular geneticist and Professor of Experimental Neuroscience at the Cambridge Institute for Medical Research, and Director of the Centre for Research in Neurodegenerative Diseases at the University of Toronto and of the Toronto Western Hospital Research Institute at the Toronto Western Hospital. He and his research team have received international scientific acclaim for their work in the genetics of neurodegenerative disease. They discovered several novel genes that cause Alzheimer's disease, and they have developed some of these genes for use as therapeutic targets and as diagnostics.

Prior to joining the Centre for Research in Neurodegenerative Diseases in 1991, Dr. St George-Hyslop was an instructor in Neurology and Genetics at Harvard Medical School and Massachusetts General Hospital. He also undertook post-doctoral training in molecular genetics at Harvard Medical School. Dr. St George-Hyslop received his M.D. degree from the University of Ottawa and post-graduate training in Internal Medicine and Neurology at the University of Toronto.

He is a member of the Canadian Genetic Diseases Network and has been honoured with the Alois Alzheimer Award, The Michael Smith Award for Excellence and is a Howard Hughes Foundation Medical Institute International Scholar, Canadian Institutes of Health Distinguished Scientist, a Fellow of the Royal Society of Canada, Fellow of the Royal Society (London), and a Foreign Member of the Institute of Medicine of the US National Academies of Science.

Andrew P. Sandham, Venture Partner, Abingworth LLP

Mr. Sandham has 30 years experience in business development and marketing within the healthcare sector. He has played a key role in building businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience, Ionix Pharmaceuticals, Syntaxin and Kymab.

Mr. Sandham is a Venture Partner with Abingworth, chairman of NeurAxon, Syntaxin and Kymab and director of PBL Technology. Mr. Sandham holds a B.Sc. in Chemistry from UEA, Norwich and a Diploma in Marketing from Chartered Institute of Marketing, UK.

Andrew J. Waitman, Chief Executive Officer, The Pythian Group

As CEO, Mr. Waitman is responsible for the strategic growth of The Pythian Group as well as over-seeing the company's worldwide operations. The Pythian Group (www.pythian.com) is a global industry-leader in remote database administration services and consulting.

From 1996 to 2008, Mr. Waitman was the Managing Partner of Celtic House Venture Partners, the largest and most successful IT venture fund in Canada, with more than $500 million under management.

He has been involved with more than 75 start-ups and a Board member of more than 25 technology start-ups.

Prior to Celtic House, Mr. Waitman held senior positions at Eagle & Partners (now Dundee Securities), Citibank and Nortel. He holds a Bachelor of Applied Science in Electrical Engineering from the University of Waterloo, and an MBA with distinction from the Richard Ivey School of Business. He is a Chartered Financial Analyst, and a member of the Association of Professional Engineers of Ontario.